Research progress of CD13-targeted molecular probe in tumor neovascularization imaging and therapy
10.3760/cma.j.issn.2095-2848.2019.11.013
- VernacularTitle: CD13靶向分子探针在肿瘤新生血管显像与治疗中的研究进展
- Author:
Minghao WU
1
;
Yanyan ZHANG
;
Lin CAO
;
Xuening ZHANG
;
Zhaoxiang YE
Author Information
1. Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin and Tianjin′s Clinical Research Center for Cancer, Tianjin 300060, China
- Publication Type:Review
- Keywords:
Neoplasms;
Neovascularization, pathologic;
Angiogenesis inhibitors;
Antigens, CD13;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2019;39(11):688-693
- CountryChina
- Language:Chinese
-
Abstract:
Tumor neovascularization plays an important role in the occurrence, development and metastasis of cancer. Non-invasive quantification and detection of tumor neovascularization is crucial for early diagnosis and prognosis assessment of cancer. Targeted molecular imaging has arisen in vascular targeting imaging and precise treatment based on the molecular characteristics of neovascularization. Aminopeptidase N (APN, or CD13) is a multifunctional membrane-bound exopeptidase that is overexpressed in neovascular endothelial cells and some tumor cells but rarely expressed in normal blood vessels, which makes it a potential target for tumor neovascularization imaging and anti-angiogenic therapy. This review summarizes the application progress and the future development trend of target molecular imaging and precise treatment based on CD13.
